FOLH1 and posterior cortical atrophy: Although the overall survival ranges from 12 to 17.6 months after initiating PSMA-targeted therapy in heavily pretreated PCa patients, there is still a subpopulation of patients who do not respond to the therapy despite PSMA-positivity [24].